Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Cancer Prev Res (Phila). 2009 Apr 28;2(5):432–439. doi: 10.1158/1940-6207.CAPR-08-0222

Table 2. Association of GST Polymorphisms and SPM Risk.

Genotypes Total SPM-Free SPM Adjusted HR1

No. % No. % No. % P-value* (95% CI)
GSTM1 0.221
 Wild-type 601 49.6 553 50.2 48 44.0 1.0
 Null 610 50.4 549 49.8 61 56.0 1.4 (0.9-2.0)
GSTT1
 Wild-type 960 79.3 875 79.4 85 78.0 0.727 1.0
 Null 251 20.7 227 20.6 24 22.0 1.1 (0.7-1.8)
GSTM1 + GSTT1 0.494
M1 Wild and T1 Wild 470 38.8 433 39.3 37 33.9 1.0
 Either M1 Null or T1 Null 621 51.3 562 51.0 59 54.2 1.3 (0.8-1.9)
M1 Null and T1 Null 120 9.9 107 9.70 13 11.9 1.6 (0.9-3.1)
Trend test P = 0.116
GSTP1_105 0.028
 Ile/Ile 484 40.1 451 41.1 33 30.3 1.0
 Ile/Val + Val/Val 723 59.9 647 58.9 76 69.7 1.7 (1.1-2.5)
GSTP1_114 0.575
Ala/Ala 1021 84.4 927 84.2 94 86.2 1.0
Ala/Val + Val/Val 189 15.6 174 15.8 15 13.8 0.8 (0.5-1.5)
No. of GSTP1 risk genotypes 0.086
 0 462 38.3 431 39.2 31 28.7 1.0
 1-2 678 56.2 609 55.5 69 63.9 1.6 (1.1-2.5)
 3-4 66 5.50 58 5.30 8 7.40 2.0 (0.9-4.3)
Trend test P = 0.018
*

P values were calculated from chi-square test

1

Adjusted for age, sex, ethnicity, smoking, and alcohol